Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunateamodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Nji, Akindeh M ^a   Ali, Innocent M ^a,b   Moyeh, Marcel N ^a   Ngongang, Eric Oliver ^a   Ekollo, Aristide M ^a   Chedjou, Jean Paul ^a   Ndikum, Valentine N ^a   Evehe, Marie S ^a   Froeschl, Guenter ^c   Heumann, Christian ^c   Mansmann, Ulrich ^c   Ogundahunsi, Olumide ^d   Mbacham, Wilfred F ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITY OF DSCHANG   (Cameroon)

^c UNIVERSITY OF MUNICH   (Germany)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Adverse events; Fever clearance; Non inferiority; Parasite clearance; PCR corrected

Indexed keywords

ALANINE AMINOTRANSFERASE; AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; HEMOGLOBIN; AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE; PIPERAQUINE; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; CAMEROONIAN; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; ENZYME ACTIVITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; OPEN STUDY; PARASITE CLEARANCE; PARENT; PARENTAL CONSENT; PLASMODIUM FALCIPARUM; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION; ADVERSE DRUG REACTION; CAMEROON; COMPARATIVE STUDY; DRUG COMBINATION; MALARIA, FALCIPARUM; PRESCHOOL CHILD;

AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; CAMEROON; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETHANOLAMINES; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; QUINOLINES; TREATMENT OUTCOME;

EID: 84924165088     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-014-0521-2     Document Type: Article

References (25)

1. WHO. World Malaria report 2011. Geneva: World Health Organization; 2011.
2. MOH. Ministère de la Santé Publique: plan stratégique national de lutte contre le paludisme 2011-2015. Cameroon: Ministry of Public Health; 2012.
3. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7:864-74.
4. Basco LK, Ndounga M, Same-Ekobo A, Yomba JC, Abodo RT, Soula G. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg. 2006;75:388-95.
5. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965-7.
6. NMCP-Cameroon. Cameroon national malaria control programme Report. Cameroon: Ministry of Public Health; 2006.
7. WHO. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria. Geneva: World Health Organization; 2003. WHO/HTM/RBM/2003.50.
8. Whegang SY, Tahar R, Foumane VN, Soula G, Gwet H, Thalabard JC, et al. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J. 2010;9:1-10.
9. Smith DL, Klein EY, McKenzie FE, Laxminarayan R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010;9:56.
10. Da Silva GT, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2008;15:120-7.
11. Create a randomisation list: [https://www.sealedenvelope.com/simplerandomiser/v1/lists]
12. Plowe CV, Bouare M, Doumbo OK, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565-8.
13. Nambozi M, Van Geertruyden J-P, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J. 2011;10:50.
14. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J. 2007;6:146.
15. The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:1-16.
16. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008;7:127.
17. Meremikwu M, Ejemot E, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, et al. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malar J. 2006;5:43.
18. NMCP-Cameroon. National Malaria Control Program report, 2012. Cameroon: Ministry of Public Health; 2012.
19. WHO/UNICEF. The Africa Malaria Report 2003. Geneva: World Health Organization; 2003.
20. Mangham LJ, Cundill B, Achonduh OA, Ambebila JN, Lele AK, Metoh TN, et al. Malaria prevalence and treatment of febrile patients at health facilities and medicine retailers in Cameroon. Trop Med Int Health. 2012;17:330-42.
21. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
22. Lokki AL, Järvelä I, Israelsson E, Maiga B, Troye-Blomberg M, Dolo D, et al. Lactase persistence genotypes and malaria susceptibility in Fulani of Mali. Malar J. 2011;10:9.
23. Modiano D, Sirima BS, Nebié I, Diallo D, Esposito F, Coluzzi M. Different response to Plasmodium falciparum malaria in west African sympatric ethnic groups. Proc Natl Acad Sci U S A. 1996;93:13206-11.
24. Anderson B, Vullo C. Did malaria select for primary adult lactase deficiency? Gut. 1994;35:1487-9.
25. Zani B, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;1, CD010927.